Tarceva erlotinib: Additional Phase III data

Additional data from the Phase IIIb SATURN trial in 889 patients with advanced, recurrent or metastatic NSCLC showed that Tarceva significantly improved overall survival (OS) by 23% vs. placebo (p=0.0...